Please login to the form below

Not currently logged in
Email:
Password:

PharmaLex appoints Dr Adam King to its regulatory team

Dr Adam King joins the German group as a senior director

Adam KingPharmaLex has appointed Dr Adam King as its senior director, regulatory affairs and service area, a role that will see him work on regulatory activities related to mergers and acquisitions.

He brings over 30 years’ experience working in the pharmaceutical industry to the Mannheim, Germany-based pharmaceutical services group. During that time he spent over 18 years in regulatory affairs, with a focus on radiopharmaceuticals, regulatory strategy development and the oversight of regulatory affairs CMC programmes.

He said: “I am excited to be part of the PharmaLex team and to spearhead a delivery service area to offer my experience for current/prospective clients in supporting the regulatory activities related to mergers and acquisitions.”

King’s most recent experiences include leading a team of regulatory consultants to complete a CMC compliance project and he has also been R&D lead for the design and implementation of an electronic document management system, publishing tools into a combined R&D and manufacturing environment.

Dr Kirsten Jacobs, executive vice president, head of global regulatory affairs at PharmaLex, said: “Adam’s appointment demonstrates our commitment to developing our existing regulatory team, helping to guide our growing customer base to regulatory milestone achievements.

“His wide-ranging experience of activities needed for M&A will provide both the UK and global team with vital skills that enable us to provide our clients with added value.”

24th August 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics